Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study

OBJECTIVES: To evaluate the impact of discontinuation of adalimumab (ADA) for 1 year in Japanese patients with early rheumatoid arthritis (RA). METHODS: This 52-week postmarketing study, HOPEFUL-2, enrolled patients who had completed HOPEFUL-1 for early RA, in which patients received either ADA + me...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Yamanaka, Hisashi, Ishiguro, Naoki, Miyasaka, Nobuyuki, Kawana, Katsuyoshi, Hiramatsu, Katsutoshi, Takeuchi, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762209/
https://www.ncbi.nlm.nih.gov/pubmed/26925252
http://dx.doi.org/10.1136/rmdopen-2015-000189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762209/
https://www.ncbi.nlm.nih.gov/pubmed/26925252
http://dx.doi.org/10.1136/rmdopen-2015-000189

Ejemplares similares